PMC:7441777 / 448-789
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T3 | 162-165 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T4 | 176-179 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T5 | 219-222 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T5 | 25-33 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 152-160 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 208-216 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T6 | 73-77 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T7 | 91-95 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T8 | 133-141 | Chemical | denotes | solution | http://purl.obolibrary.org/obo/CHEBI_75958 |
T9 | 271-285 | Chemical | denotes | antiviral drug | http://purl.obolibrary.org/obo/CHEBI_36044 |
T10 | 271-280 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T11 | 281-285 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 219-234 | http://purl.obolibrary.org/obo/GO_0039703 | denotes | RNA replication |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
44 | 192-196 | Gene | denotes | RdRp | Gene:43740578 |
56 | 208-218 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
77 | 25-33 | Disease | denotes | COVID-19 | MESH:C000657245 |
78 | 152-160 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 35-161 | Sentence | denotes | Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. |
T10 | 162-293 | Sentence | denotes | RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. |